Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
ELDN has been the topic of several other reports. Rodman & Renshaw assumed coverage on Eledon Pharmaceuticals in a research report on Tuesday, July 21st. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings raised Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $10.00.
Get Our Latest Analysis on Eledon Pharmaceuticals
Eledon Pharmaceuticals Price Performance
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Equities analysts anticipate that Eledon Pharmaceuticals will post -0.74 EPS for the current fiscal year.
Institutional Investors Weigh In On Eledon Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its stake in shares of Eledon Pharmaceuticals by 212.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 127,933 shares of the company’s stock valued at $324,000 after purchasing an additional 87,010 shares during the period. StoneX Group Inc. purchased a new stake in Eledon Pharmaceuticals during the third quarter worth $29,000. Claro Advisors Inc. acquired a new stake in Eledon Pharmaceuticals during the third quarter valued at $40,000. Farmers & Merchants Investments Inc. grew its position in Eledon Pharmaceuticals by 1,072.6% during the third quarter. Farmers & Merchants Investments Inc. now owns 74,123 shares of the company’s stock valued at $188,000 after buying an additional 67,802 shares during the period. Finally, Daytona Street Capital LLC grew its position in Eledon Pharmaceuticals by 12.9% during the third quarter. Daytona Street Capital LLC now owns 91,666 shares of the company’s stock valued at $231,000 after buying an additional 10,500 shares during the period. Institutional investors and hedge funds own 56.77% of the company’s stock.
Eledon Pharmaceuticals Company Profile
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS.
Recommended Stories
- Five stocks we like better than Eledon Pharmaceuticals
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
